A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions in the eye to be treated are excluded:
• •External ocular infection.
• •Other herpetic infections of the retina, toxoplasma retinochoroiditis, or other disease of the fundus.
• •Ocular condition that will obstruct visualization of the posterior ocular structures.
• •Retinal detachment.
• •Silicone oil in eye.
• •Patients with the following other symptoms or conditions are excluded:
• •Known or suspected allergy to phosphorothioate oligonucleotides.
• •Syphilis.
• •Retinal pigment epithelial stippling not associated with CMV retinitis.
• •Pseudoretinitis pigmentosa.
• •Chronic diarrhea that would impair absorption of oral ganciclovir.
• •Intolerance to ganciclovir.
• •Concurrent Medication:
• •Excluded:
• •Foscarnet or other anti-CMV agents other than ganciclovir.
• •Mellaril.
• •Stelazine.
• •Thorazine.
• •Clofazimine.
• •Ethambutol/fluconazole combination.
• •Investigational medications for CMV retinitis.
• •Concurrent Treatment:
• •Excluded:
• •Investigational procedures for CMV retinitis.
• •Patients with the following prior conditions are excluded:
• •History of surgery to correct retinal detachment in eye to be treated.
• •History of intolerance to ISIS 2922.
• •Prior Medication:
• •Excluded:
• •Prior ganciclovir implant for CMV retinitis.
• •More than 4 months of prior ganciclovir.